Alpha Cognition Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACOG Nasdaq 2830 www.alphacognition.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Cognition Inc.

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - Jan 14th, 2025 1:30 pm
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - Jan 8th, 2025 1:30 pm
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - Jan 6th, 2025 1:30 pm
Alpha Cognition Announces Partial Exercise of Over-allotment Option - Dec 16th, 2024 7:56 pm
Alpha Cognition Announces Voluntary Delisting from CSE - Dec 12th, 2024 11:41 pm
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Dec 11th, 2024 1:30 pm